GeneCure Biotechnologies is at the forefront of developing innovative gene therapy technologies aimed at treating both genetic and acquired human diseases. Central to their approach is the patented SimVec gene transfer technology, which utilizes a primate lentivirus to safely and efficiently deliver therapeutic genes into primary human cells. This technology is particularly advantageous as it allows for stable long-term expression of therapeutic genes, overcoming limitations associated with traditional retroviral vectors that struggle to infect non-dividing cells. GeneCure's research focuses on creating both preventative and therapeutic vaccines for diseases such as HIV, Hepatitis B and C, and Severe Acute Respiratory Syndrome (SARS), with several products currently in various stages of development.

In addition to vaccine development, GeneCure's SimVec technology has broad applications in gene-based therapeutics, including gene silencing, stem cell manipulation, and the creation of transgenic animals. The ability to deliver genes into a wide range of cell types, including those that are typically resistant to other vectors, positions GeneCure to explore novel therapeutic avenues and enhance our understanding of gene function. Their commitment to safety and efficacy is underscored by preclinical studies demonstrating the technology's favorable safety profile, paving the way for future clinical applications in treating a variety of human diseases.

United States

GeneCure Biotechnologies is a biotechnology company that focuses on developing gene therapy based technologies to treat genetic and acquired human diseases.

GeneCure Biotechnologies

Company Details